These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30353042)

  • 21. Laser Therapy Versus Anti-VEGF Agents for Treatment of Retinopathy of Prematurity.
    Leskov I; Mukai S
    Int Ophthalmol Clin; 2015; 55(4):81-90. PubMed ID: 26322428
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
    Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
    Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of retinopathy of prematurity.
    Fleck BW
    Arch Dis Child Fetal Neonatal Ed; 2013 Sep; 98(5):F454-6. PubMed ID: 23813885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.
    Isaac M; Tehrani N; Mireskandari K;
    Eye (Lond); 2016 Mar; 30(3):333-41. PubMed ID: 26869159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.
    Nicoară SD; Ștefănuţ AC; Nascutzy C; Zaharie GC; Toader LE; Drugan TC
    Med Sci Monit; 2016 Apr; 22():1192-209. PubMed ID: 27062023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity.
    Gunay M; Sekeroglu MA; Bardak H; Celik G; Esenulku CM; Hekimoglu E; Bardak Y
    Strabismus; 2016 Jun; 24(2):84-8. PubMed ID: 27120579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal bevacizumab treatment reduces ocular blood flow in retinopathy of prematurity: a four-case report.
    Matsumoto T; Itokawa T; Shiba T; Tomita M; Hine K; Mizukaki N; Yoda H; Hori Y
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2241-2247. PubMed ID: 29980917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab treatment for retinopathy of prematurity in South Africa.
    Pollock T
    S Afr Med J; 2017 Feb; 107(3):178-179. PubMed ID: 28281419
    [No Abstract]   [Full Text] [Related]  

  • 30. [New therapeutic approaches in the treatment of retinopathy of prematurity].
    Jandeck C
    Klin Monbl Augenheilkd; 2009 Nov; 226(11):914-20. PubMed ID: 19798624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fulminate retinopathy of prematurity - clinical characteristics and laser outcome.
    Shah PK; Narendran V; Saravanan VR; Raghuram A; Chattopadhyay A; Kashyap M; Morris RJ; Vijay N; Raghuraman V; Shah V
    Indian J Ophthalmol; 2005 Dec; 53(4):261-5. PubMed ID: 16333175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective.
    Chan-Ling T; Gole GA; Quinn GE; Adamson SJ; Darlow BA
    Prog Retin Eye Res; 2018 Jan; 62():77-119. PubMed ID: 28958885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
    Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
    Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antivascular endothelial growth factor in the treatment of retinopathy of prematurity.
    Patel JR; Ranjan SS; Wasserman BN
    Curr Opin Ophthalmol; 2016 Sep; 27(5):387-92. PubMed ID: 27206263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypotension Associated With Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity.
    Wu LH; Yang YH; Lin CH; Lin YJ; Cheng CL
    Pediatrics; 2016 Feb; 137(2):e20152005. PubMed ID: 26743817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral propranolol in early stages of retinopathy of prematurity.
    Bancalari A; Schade R; Muñoz T; Lazcano C; Parada R; Peña R
    J Perinat Med; 2016 Jul; 44(5):499-503. PubMed ID: 26845715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Off-label use of intravitreal bevacizumab for severe retinopathy of prematurity].
    Alba LE; Zaldua RA; Masini RA
    Arch Soc Esp Oftalmol; 2015 Feb; 90(2):81-6. PubMed ID: 25459682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5.
    Jalali S; Balakrishnan D; Zeynalova Z; Padhi TR; Rani PK
    Arch Dis Child Fetal Neonatal Ed; 2013 Jul; 98(4):F327-33. PubMed ID: 23269586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of Plasma Cytokine Profile Changes in Bevacizumab-Treated Retinopathy of Prematurity Infants.
    Kong L; Demny AB; Sajjad A; Bhatt AR; Devaraj S
    Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1649-54. PubMed ID: 27054517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.